drugset
drugset / Trial / NCT05321979

Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

NCT05321979 ↗

Phase 3 Completed 253 enrolled Medytox Korea
NaSingle-groupOpen-labelTreatment

Summary

This study is intended to evaluate long-term safety and efficacy of MBA-P01 in treatment of glabellar lines.

Timeline

Start
2022-02-07
Primary completion
2023-05-30
Completion
2023-05-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject MBA-P01 Protein / enzyme biologic 20 iu —

Indications

No indication recorded.